| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6e7b8a7632054e507d98a54cd3d11573 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F13-005
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-0478 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K103-10 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K51-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F13-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-04 |
| filingDate |
2017-06-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f75ee027f94411970a967460a9c4b813
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_032885fa5400ef95fd2d60def186d989
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0403eaa4a2116ddcda322a860dfb98cc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4f5210c90ee355872d939297b1272b2f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bee4ae024f81f1d58ebd018177e48819
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d042ba5652bd391b57b6ca1bb64b60a1 |
| publicationDate |
2017-12-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2017222362-A1 |
| titleOfInvention |
99mtc-edda/hynic-ipsma as a radiopharmaceutical for detecting the overexpression of prostate-specific membrane antigen |
| abstract |
The invention relates to a novel radiopharmaceutical that inhibits the prostate-specific membrane antigen (iPSMA), containing hydrazinonicotinamide (HYNIC) as a critical chemical group in increasing in the lipophilicity of the molecule for binding to the hydrophobic sites of the PSMA, combined with the conventional use of HYNIC as a chelating agent for radiometal 99m Tc, in which the ethylenediaminetetraacetic acid (EDDA) is used to complete the coordination sphere of the radiometal. The novel radiopharmaceutical 99m Tc-EDDA/HYNIC-iPSMA detects, with high affinity and sensitivity in vivo , the overexpressed PSMA protein in prostate cancer cells using SPECT molecular imaging techniques in nuclear medicine. The aim of the invention is to provide a novel specific radiopharmaceutical (radiopharmaceutical for molecular targets) for SPECT, with high sensitivity for the detection of tumours with overexpression of PSMA. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3766893-A4
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3721907-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022253785-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019177449-A1 |
| priorityDate |
2016-06-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |